This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 6Hepatitis B virus
- 3Antiviral agents
- 3Hepatitis--Animal models
- 3Viruses--Reproduction
- 1CRISPR
- 1Galactose
-
Fall 2022
Hepatitis B virus (HBV) has infected two billion people worldwide, culminating in approximately 250 million chronic carriers. Chronic HBV carriers are at high risk of developing severe liver diseases, such as cirrhosis and cancer, resulting in an estimated 600,000 HBV-associated deaths annually....
-
Using designed zinc finger proteins to inhibit hepatitis B virus transcription in tissue culture
DownloadFall 2012
Upon infection with hepatitis B virus (HBV) the result will be either a chronic infection or clearance of the virus. For the chronic carriers of HBV, therapy is primarily limited to nucleoside analogs, which inhibits viral replication and prevents production of progeny virus, however the...